Thiogenesis Therapeutics Corp (TTI) News

'A Prodrug for Mito-Dysfunction' Offering 113% Upside Potential - Thiogenesis Therapeutics (TTI.v) Research Report Summary: https://x.com/StckMasterFlash/status/1871347807430291939

Focused on a cutting-edge approach to rare disease treatment with a solid foundation for growth, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company advancing its lead product TTI-0102 to treat rare mitochondrial diseases including MELAS and Leigh Syndrome (LS). TTI offers a high-risk, high-reward investment opportunity, driven by its innovative approach to treating rare mitochondrial diseases and the potential for substantial market penetration across its targeted indications.

Focused on a cutting-edge approach to rare disease treatment with a solid foundation for growth, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company advancing its lead product TTI-0102 to treat rare mitochondrial diseases MELAS and Leigh Syndrome (LS): https://x.com/StckMasterFlash/status/1866620308544786857

MELAS: Phase 2 trial begins in early 2025 (Netherlands & France) targeting 15,000 U.S. and 20,000 EU patients.
Leigh Syndrome: IND filing planned for early 2025 for this severe, untreatable disorder affecting 1 in 40,000 births.

Yesterday, Thiogenesis Therapeutics (TTI.v) presented significant updates on its two clinical programs that are advancing its lead product, TTI-0102 which aims to address oxidative stress and improve outcomes for rare, debilitating conditions that affect a range of patients worldwide: https://x.com/StckMasterFlash/status/1866620308544786857

Having submitted its Clinical Trial Application Part II in Europe, TTI plans to launch a Phase 2 trial in early 2025 in the Netherlands and France for MELAS, focusing on physical endurance and biomarker analysis in 12 patients. For Leigh Syndrome, TTI collaborated with a leading U.S. children’s hospital and engaged in a pre-IND meeting with the FDA, paving the way for an IND submission and a Phase 2a trial in early 2025.

Today, Thiogenesis Therapeutics (TTI.v), a clinical-stage biotechnology company, presented updates on its two clinical programs for mitochondrial diseases during the UMDF "Bench-to-Bedside" webcast: https://www.newsfilecorp.com/release/233143/Thiogenesis-Announces-Presentation-on-UMDF-Webcast-Featuring-Clinical-Trials-in-Mitochondrial-Disease

TTI is advancing its lead product, TTI-0102, with promising applications in treating MELAS, a rare disorder affecting 15,000 patients in the U.S. and 20,000 in the EU, and Leigh Syndrome (LS), which is diagnosed in infancy and affects 1 in 40,000 births (More info: https://www.reddit.com/r/RichTogether/comments/1gvx18y/with_45m_in_the_bank_a_low_burn_rate_strong/)

Last week, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v) announced attaining DTC eligibility in the US, facilitating electronic settlement of its common shares; a significant milestone aligning with the company's plans for a future U.S. listing: https://www.newsfilecorp.com/release/231667/Thiogenesis-Announces-DTC-Eligibility-in-the-U.S.-and-Other-Updates 

Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, TTI is focused on developing novel thiol-based compounds to address mitochondrial dysfunction and its related diseases -  a substantial addressable market as mitochondrial diseases collectively affect millions worldwide, with very few effective therapies currently available: https://x.com/StckMasterFlash/status/1859742853578076171

Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, Thiogenesis Therapeutics (TTI.v) is a biopharmaceutical company focused on developing novel thiol-based compounds to address mitochondrial dysfunction and its related diseases: https://drive.google.com/file/d/1Obahg9CXnD__6WbReUT93Sgzu6C9EoD_/view

Representing a growing market segment in the pharmaceutical industry, estimates suggest the mitochondrial disease therapies market to be worth USD 1,817 million by 2030. Thus,

By leveraging its innovative compounds and focusing on pediatric diseases with no approved therapies, TTI has the potential to make significant strides in addressing critical gaps alongside addressing multiple indications within this growing market, presenting significant commercial and therapeutic opportunities.

Insightful breakdown of Thiogenesis Therapeutics (TTI.v) and the market opportunity its taking advantage of by focusing on pediatric diseases with unmet medical needs including pediatric NASH which currently has zero approved drugs or treatments: https://x.com/airic101/status/1856816752128143615

Targeting a large addressable market in developing therapeutic compounds for pediatric diseases with unmet medical needs, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company: https://x.com/StckMasterFlash/status/1856131383535542718

Notably, TTI recently announced the approval of its European patent for the treatment of Cysteamine Sensitive Disorders, a medical condition characterized by cellular dysfunction, which complements the companys previous patent approvals in the US and Japan, as well as aligns with TTI's development of TTI-0102, a novel thiol-based prodrug designed to address mitochondrial diseases and related metabolic disorders by enhancing cellular antioxidant defenses.

Developing therapeutic compounds for pediatric diseases with unmet medical needs and a large addressable market, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v), recently announced the approval of its European patent for the treatment of Cysteamine Sensitive Disorders, a medical condition characterized by cellular dysfunction: https://x.com/StckMasterFlash/status/1856131383535542718

Complementing previous patent approvals in the US and Japan, the IP protection aligns with TTI's development of TTI-0102, a novel thiol-based prodrug designed to address mitochondrial diseases and related metabolic disorders by enhancing cellular antioxidant defenses.